Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT04410003

Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis

Led by Western University, Canada · Updated on 2024-10-17

100

Participants Needed

1

Research Sites

269 weeks

Total Duration

On this page

Sponsors

W

Western University, Canada

Lead Sponsor

E

European Bioinformatics Institute

Collaborating Sponsor

AI-Summary

What this Trial Is About

Patients with unexplained atherosclerosis (severe atherosclerosis not explained by traditional risk factors) will receive fecal microbial transplants (FMT) from patients with a Protected phenotype (patients who have high levels of risk factors but little or no carotid atherosclerosis). The objective is to determine what changes in the intestinal microbiome are associated with a decline in plasma levels of toxic metabolites of the itnestinal microbiome such as trimethylamine N-oxide (TMAO) and p-cresylsulfate. The intention is to develop an ecosystem therapeutic of cultured bacteria to treat atherosclerosis.

CONDITIONS

Official Title

Metabolic and Metagenomic Effects of Intestinal Microbiome Repopulation in Unexplained Atherosclerosis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Severe atherosclerosis with total plaque area in the top quartile (>119 mm2), not explained by traditional risk factors (residual score  2)
Not Eligible

You will not qualify if you...

  • Unable or unwilling to provide informed consent
  • Unwilling to ingest stool capsules at baseline
  • Moderate to severe renal failure (eGFR <50)
  • Immunosuppressed patients
  • Patients with cancer
  • Unstable angina
  • Planned carotid revascularization
  • Conditions expected to reduce survival to less than 1 year, including age over 80 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Stroke Prevention & Atherosclerosis Research Centre, Robarts Research Institute

London, Ontario, Canada, N6G 2V4

Actively Recruiting

Loading map...

Research Team

J

J. David Spence, M.D.

CONTACT

L

Leslie Paddock, R.N.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here